Jim Cramer ran through all 32 companies in the Investing Club portfolio during the February Monthly Meeting on Thursday. Here's a rapid-fire look at what he had to say on each stock. Apple : Some obstacles facing Apple include the stock's unusually high valuation, sluggish iPhone growth and continuous uncertainty in its China market. Still, Apple remains an "own, don't trade" name in our portfolio. Apple has a lot going for it like its growing service revenue stream. Abbott Laboratories : Consider Abbott the poster child of the "comeback kids" in our portfolio. The stock is up nearly 20% since…